GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ViroPharma, Inc. (FRA:VPH) » Definitions » Cyclically Adjusted Book per Share

ViroPharma, (FRA:VPH) Cyclically Adjusted Book per Share : €0.00 (As of Sep. 2013)


View and export this data going back to . Start your Free Trial

What is ViroPharma, Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

ViroPharma,'s adjusted book value per share for the three months ended in Sep. 2013 was €7.589. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.00 for the trailing ten years ended in Sep. 2013.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-06-22), ViroPharma,'s current stock price is €36.08. ViroPharma,'s Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2013 was €0.00. ViroPharma,'s Cyclically Adjusted PB Ratio of today is .


ViroPharma, Cyclically Adjusted Book per Share Historical Data

The historical data trend for ViroPharma,'s Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ViroPharma, Cyclically Adjusted Book per Share Chart

ViroPharma, Annual Data
Trend Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ViroPharma, Quarterly Data
Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ViroPharma,'s Cyclically Adjusted Book per Share

For the Biotechnology subindustry, ViroPharma,'s Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ViroPharma,'s Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ViroPharma,'s Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where ViroPharma,'s Cyclically Adjusted PB Ratio falls into.



ViroPharma, Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ViroPharma,'s adjusted Book Value per Share data for the three months ended in Sep. 2013 was:

Adj_Book= Book Value per Share /CPI of Sep. 2013 (Change)*Current CPI (Sep. 2013)
=7.589/98.7900*98.7900
=7.589

Current CPI (Sep. 2013) = 98.7900.

ViroPharma, Quarterly Data

Book Value per Share CPI Adj_Book
200312 -0.233 77.758 -0.296
200403 -0.739 79.066 -0.923
200406 -0.904 80.037 -1.116
200409 -0.999 80.121 -1.232
200412 -0.730 80.290 -0.898
200503 -0.091 81.555 -0.110
200506 0.723 82.062 0.870
200509 1.185 83.876 1.396
200512 4.573 83.032 5.441
200603 3.980 84.298 4.664
200606 4.017 85.606 4.636
200609 4.381 85.606 5.056
200612 4.398 85.142 5.103
200703 4.355 86.640 4.966
200706 3.955 87.906 4.445
200709 4.032 87.964 4.528
200712 4.046 88.616 4.511
200803 3.954 90.090 4.336
200806 4.140 92.320 4.430
200809 4.731 92.307 5.063
200812 6.187 88.697 6.891
200903 6.857 89.744 7.548
200906 5.709 91.003 6.197
200909 5.663 91.120 6.140
200912 6.647 91.111 7.207
201003 6.370 91.821 6.853
201006 7.340 91.962 7.885
201009 7.195 92.162 7.712
201012 7.437 92.474 7.945
201103 6.563 94.283 6.877
201106 7.080 95.235 7.344
201109 7.043 95.727 7.268
201112 8.007 95.213 8.308
201203 7.812 96.783 7.974
201206 9.842 96.819 10.042
201209 9.298 97.633 9.408
201212 8.836 96.871 9.011
201303 8.284 98.209 8.333
201306 8.241 98.518 8.264
201309 7.589 98.790 7.589

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


ViroPharma,  (FRA:VPH) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


ViroPharma, Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of ViroPharma,'s Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


ViroPharma, (FRA:VPH) Business Description

Industry
Traded in Other Exchanges
N/A
Address
ViroPharma, Inc. was incorporated in Delaware in September 1994 and commenced operations in December 1994. It is a biotechnology company which develops and commercializes products that address serious diseases, used by physician specialists or in hospital settings. The Company's main development programs include C1 esterase inhibitor and a non-toxigenic strain of C. The Company markets and sells Cinryze in the United States for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema. Cinryze is a C1 esterase inhibitor therapy for routine prophylaxis against HAE, also known as C1 inhibitor deficiency, a rare, severely debilitating, life-threatening genetic disorder. Cinryze was obtained in October 2008, and On 8 January 2010, the company obtained expanded rights to commercialize Cinryze and future C1-INH derived products in certain European countries and other territories throughout the world as well as rights to develop future C1-INH derived products for additional indications. The Company also markets and sells Vancocin HCl capsules, the oral capsule formulation of vancomycin hydrochloride, in the U.S. and its territories. Vancocin is a potent antibiotic approved by the U.S. Food and Drug Administration, or FDA, to treat antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infection, or C. difficile, and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. The Company's product development portfolio is consists of programs such as C1 esterase inhibitor [human], maribavir for cytomegalovirus infection, VP20621: prevention of recurrent CDAD and VP20629: treatment of Friedreich's Ataxia. The Company is working on developing further therapeutic uses; potential additional indications in other C1 mediated diseases, and alternative modes of administration for C1 esterase inhibitor. It is also developing VP20621 for the treatment and prevention of CDAD. On September 30, 2011, it entered into a license agreement for the worldwide rights of Intellect Neurosciences, Inc. to its clinical stage drug candidate, VP-20629, which is a naturally occurring, small molecule that has potent anti-oxidant properties that can protect against neurodegenerative disease. Its main competitors include both public and private entities, including well-known, large pharmaceutical companies, chemical companies, biotechnology companies and research institutions.

ViroPharma, (FRA:VPH) Headlines

No Headlines